Thomas H. Kean
Thomas H. Kean (R-NJ) bought $15K-$50K of $CHKP (Check Point Software Technologies Ltd. - Ordinary Shares) on Jul 29, 2025, part of 6 transactions in this filing (2 buys, 3 sells).
HillSignal flagged 5 timing concerns on this filing — trades that line up closely with related legislative or contract activity.
Price Movement Since Trade
How the largest positions have moved from the trade date to the most recent close.
Suspicious Timing Detected
5 flagsRep. Thomas H. Kean bought $1,001 - $15,000 in $ABT on 2025-07-21 — 45 days before HR5127 ("PrEP and PEP are Prevention Act") was introduced, a bill that could increase demand for related medical products.
Rep. Thomas H. Kean bought $1,001 - $15,000 in $ABT on 2025-07-21 — 58 days before HR5343 ("Ensuring Patient Access to Critical Breakthrough Products Act") advanced out of committee, indicating significant legislative momentum.
Rep. Thomas H. Kean sold $15,001 - $50,000 in $JNJ on 2025-07-31 — 50 days before HR5526 ("Biosimilar Red Tape Elimination Act") was introduced, a bill that could reduce market exclusivity for some pharmaceutical products.
These flags identify timing coincidences between stock trades and legislative activity. They do not imply wrongdoing. Click any bill number or ticker to see the full analysis.
Share This Filing
All Transactions
| Type | Ticker | Asset | Amount | Trade Price | Current | Change | Date |
|---|---|---|---|---|---|---|---|
| BUY | $CHKP | Check Point Software Technologies Ltd. - Ordinary Shares | $15K-$50K | $218.33 | — | — | Jul 29, 2025 |
| BUY | $ABT | Abbott Laboratories Common Stock | $1K-$15K | $124.42 | — | — | Jul 21, 2025 |
| PARTIAL SELL | $JNJ | Johnson & Johnson Common Stock | $15K-$50K | $164.74 | — | — | Jul 31, 2025 |
| PARTIAL SELL | $SYK | Stryker Corporation Common Stock | $15K-$50K | $392.73 | — | — | Jul 31, 2025 |
| SELL | $ADBE | Adobe Inc. - Common Stock | $1K-$15K | $370.70 | — | — | Jul 29, 2025 |
| EXCHANGE | $LBRDK | Liberty Broadband Corporation - Class C Common Stock | $1K-$15K | $87.72 | — | — | Jul 15, 2025 |
Connected Legislative Activity
10 signalsThese bills and contracts share tickers or sectors with this filing's trades.
PrEP and PEP are Prevention Act
The PrEP and PEP are Prevention Act (HR5127) mandates zero-cost coverage of HIV prevention drugs and associated lab monitoring across all US insurance programs. This early-stage bipartisan bill creates direct volume upside for Gilead ($GILD) on branded PrEP, Viatris ($VTRS) on generic PrEP, and Labcorp ($LH) on mandatory diagnostic services. Merck ($MRK) is excluded from the causal chain because its islatravir candidate is not FDA-approved and the bill only covers approved drugs.
Biosimilar Red Tape Elimination Act
The Biosimilar Red Tape Elimination Act (HR5526) would remove FDA interchangeability study requirements, speeding market entry for $VTRS and $TEVA biosimilars. Market data shows $VTRS +11.55% and $TEVA +17.73% over 30 days, consistent with investors pricing in this regulatory catalyst. Innovators $AMGN (-2.11% 30-day), $JNJ (-5.95%), and $BIIB (+4.18%) face structural margin pressure as pharmacy-level substitution becomes automatic upon biosimilar approval.
AI-Related Job Impacts Clarity Act
The AI-Related Job Impacts Clarity Act (S3108) is an early-stage Senate bill requiring quarterly disclosures of AI-driven job changes. It imposes new compliance costs on major AI investors like Microsoft, Alphabet, Amazon, NVIDIA, and Meta without allocating any funding. Market impact is currently low given the bill's procedural status, but the transparency risk is real for AI-heavy companies.
End the Vaccine Carveout Act
The End the Vaccine Carveout Act (HR 4668) is an early-stage bill with 29 cosponsors that would eliminate the PREP Act liability shield for vaccine manufacturers, exposing $PFE, $MRNA, $GSK, and $JNJ to direct civil lawsuits for vaccine-related injuries. The bill has no near-term passage probability — it was referred to committee in July 2025 with zero further action — but its reintroduction signals continued legislative risk for the vaccine liability framework. Real market data shows all four tickers are down over the trailing 30 days ($PFE -5.09%, $MRNA -7.03%, $GSK -5.16%, $JNJ -5.87%), consistent with broader pharma weakness rather than a discrete bill-event reaction.
To authorize the extension of nondiscriminatory treatment (normal trade relations treatment) to products of certain countries.
HR5917 is an early-stage procedural bill authorizing the President to extend normal trade relations to most countries by waiving the Jackson-Vanik amendment. It authorizes no funding and changes no current tariff levels. Real market data shows $WMT at $130.81 near its 52-week high, with a 30-day gain of 5.25%, and $AAPL up 8.8% in 30 days—indicating that favorable trade expectations are already priced in. The bill faces a long legislative path with no near-term market impact.
Price Gouging Prevention Act of 2025
The Price Gouging Prevention Act of 2025 (HR4528) is an early-stage House bill capping corporate margins during 'exceptional market shocks'. Currently referred to committee with zero appropriations, the bill poses a structural long-term regulatory risk to all large-cap companies with pricing flexibility, particularly retailers ($WMT, $AMZN) and integrated energy ($XOM, $CVX). Near-term market impact is low given early legislative stage, but the bill's breadth — covering all goods and services — represents a significant expansion of FTC authority if it advances.
Protecting Free Vaccines Act of 2025
The Protecting Free Vaccines Act of 2025 is an early-stage bill (S.2857) that codifies existing ACIP vaccine coverage mandates through 2030 without expanding coverage, creating new funding, or changing market dynamics. The bill's impact on vaccine manufacturers and insurers is neutral: it removes regulatory uncertainty but provides no growth catalyst. All S&P 500 stocks covered have been declining over the past 30 days, with MRNA down 13.49% in the last week alone. This bill does not alter those trends.
Protecting Free Vaccines Act
The Protecting Free Vaccines Act (HR5448) is an early-stage House bill that would mandate zero-cost-sharing coverage for ACIP-recommended vaccines across Medicare, Medicaid, CHIP, and private insurance until 2030. Vaccine manufacturers like Pfizer and Moderna are structurally positioned to benefit from increased utilization, while health insurers like UnitedHealth face higher claims costs. CVS has mixed exposure as both insurer (Aetna) and vaccine administrator (CVS Pharmacy). The bill is referred to three committees with 72 cosponsors and has a Senate companion bill (S2857), but a long legislative path remains.
Ensuring Patient Access to Critical Breakthrough Products Act
HR5343 would force Medicare to provide immediate 4-year coverage for FDA breakthrough devices, directly benefiting large medical device manufacturers by eliminating the current 1-3 year coverage lag. The bill passed the Ways & Means committee 37-3 but awaits floor action. Despite bearish recent price action (MDT -8.2%, ABT -11%, BDX -7.3% in 30 days), this bill represents a structural catalyst for device revenue acceleration.
Medical Device Nonvisual Accessibility Act of 2025
HR5605, the Medical Device Nonvisual Accessibility Act, is in early committee stage with zero appropriation — a compliance mandate, not a spending bill. Home medical device makers face moderate retrofit costs but no immediate revenue impact. Market data shows medtech stocks already under broad 30-day pressure (-8% to -11%), and this bill adds a minor regulatory cost layer without near-term catalyst.
Other Filings by Thomas H. Kean
Free — no credit card
Get the next Kean trade the day it's disclosed
HillSignal tracks every Congressional stock filing and federal contract, scores its market impact with AI, and emails you the ones that matter — before they hit the news.
Weekly digest — the congressional activity that actually moved markets that week, in plain English. Free, one email.
Free forever plan · No credit card · Unsubscribe in one click
Want the live terminal too? Create a free account →
Data sourced from the U.S. House of Representatives Office of the Clerk Financial Disclosure system. Stock prices from Financial Modeling Prep. Suspicious timing flags identify coincidences between stock trades and legislative activity and do not imply any wrongdoing or illegal activity. This is not financial advice.